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Abstract
Background: Coronary artery disease and ischemic heart disease are leading causes of heart failure and death. Reduced
blood flow to heart tissue leads to decreased heart function and symptoms of heart failure. Therapies to improve heart
function in chronic coronary artery disease are important to identify. HMG-CoA reductase inhibitors (statins) are an
important therapy for prevention of coronary artery disease, but also have non-cholesterol lowering effects. Our prior work
showed that pravastatin improves contractile function in the chronically ischemic heart in pigs. Endothelial progenitor cells
are a potential source of new blood vessels in ischemic tissues. While statins are known to increase the number of early
outgrowth endothelial progenitor cells, their effects on late outgrowth endothelial progenitor cells (LOEPCs) and capillary
density in ischemic heart tissue are not known. We hypothesized that statins exert positive effects on the mobilization and
growth of late outgrowth EPCs, and capillary density in ischemic heart tissue.
Methodology/Principal Findings: We determined the effects of statins on the mobilization and growth of late outgrowth
endothelial progenitor cells from pigs. We also determined the density of capillaries in myocardial tissue in pigs with chronic
myocardial ischemia with or without treatment with pravastatin. Pravastatin therapy resulted in greater than two-fold
increase in CD31+ LOEPCs versus untreated animals. Addition of pravastatin or simvastatin to blood mononuclear cells
increased the number of LOEPCs greater than three fold in culture. Finally, in animals with chronic myocardial ischemia,
pravastatin increased capillary density 46%.
Conclusions: Statins promote the derivation, mobilization, and clonal growth of LOEPCs. Pravastatin therapy in vivo
increases myocardial capillary density in chronically ischemic myocardium, providing an in vivo correlate for the effects of
statins on LOEPC growth in vitro. Our findings provide evidence that statin therapy can increase the density of capillaries in
the chronically ischemic heart.
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Introduction
Coronary artery disease is the leading cause of heart failure in the
United States [1]. The primary goal of therapy in patients with heart
failure or weakened cardiac muscle function due to coronary artery
disease is to restore blood flow to prevent damage to heart muscle from
chronic ischemia and prevent death of cardiac myocytes. In some
patients coronary artery disease persists unidentified, or cannot be
revascularized, resulting in chronically ischemic myocardium, with
regional contractile dysfunction. These clinical findings can result in
heart failure manifesting as shortness of breath with exertion, weight
gain, and retention of fluid. Therapies to promote improved heart
muscle function are an important goal to improve symptoms and
prevent death in patients with coronary artery disease and heart failure.
Therapy with HMG-CoA reductase inhibitors (statins) is an
important component of medical treatment for coronary artery
disease primarily for their cholesterol lowering benefits to prevent
the progression and recurrence of disease in the heart. However,
statins have additional non-cholesterol lowering benefits that are
less well described. In our prior study, we found that therapy with
the HMG-CoA reductase inhibitor pravastatin mobilized c-kit+
bone marrow cells to the heart in animals with chronic myocardial
ischemia with regional myocardial dysfunction, leading to
improved contractile function without significantly affecting
myocardial blood flow [2]. However, the effects of statins on
endothelial progenitor cells and myocardial capillary density in
the chronically ischemic heart are not known, and somewhat
controversial. Some have suggested that therapy with statins
impairs angiogenesis in the chronically ischemic heart [3].
There are several potential sources of new blood vessels in the
heart including differentiation of local resident vascular progenitor
cells [4] via vasculogenesis, formation of new vessels by
recruitment of endothelial progenitor cells from the blood stream,
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progenitor cells (EPCs) have been defined in various ways based
on cell surface marker phenotypes including CD133 and VEGFR2
expression, or by cultured based assays [5]. However, recent
evidence indicates that that an additional cell type contained in
blood mononuclear cells known as late outgrowth endothelial
progenitor cells (LOEPCs) have distinct growth properties from
other EPC cell types, including adherence to collagen coated
substrates, the ability to undergo serial replating, clonogenic
growth in culture, and the ability to form functional vessels in vivo
[6]. Our goal was to determine how HMG-CoA reductase
inhibitors affected the mobilization, derivation, and clonogenic
growth of LOEPCs as a surrogate for effects of statins on
angiogenesis, and determine how statins affect capillary density in
animals with chronically ischemic myocardium.
Materials and Methods
Procedures and protocols conformed to institutional guidelines
for the care and use of animals in research.
Allour animalwork on pigs was performed according to a standing
protocol approved by the SUNY at Buffalo School of Medicine and
Biomedical Sciences IACUC (Protocol Number MED022011Y).
Briefly, all studies where blood was to obtained, or studies on pigs
with hibernating myocardium were performed on animals that were
sedated using tiletamine (50 mg/mL) and zolazepam (50 mg/mL),
followed by intubation and sedation with 0.5–2% isoflurane-oxygen
mixture. Terminal procedures were performed using a deep surgical
plane of anesthesia prior to euthanasia.
Preparation of Mononuclear Cells from Porcine
Peripheral Blood
Porcine mononuclear cells (MNCs) were isolated as described
[7,8] with minor modifications. Briefly, peripheral blood
was collected into cell preparation tubes for density gradient
centrifugation (BD Vacutainer CPT, Catalog number 362761),
centrifuged for 30 minutes at room temperature, 1500 6g. After
centrifugation, the supernatant was discarded, and the mononu-
clear fraction was retained, washed twice in PBS and resuspended
in EBM-2 medium (Lonza, Walkersvile,MD) supplemented with
10% fetal bovine serum (FBS; Hyclone,Logen,UT) (complete
EGM-2 medium).
Culturing of MNCs for Late Outgrowth Endothelial
Progenitor Cells (LOEPCs)
MNCs in complete EGM-2 medium were seeded onto six-well
tissue culture plates (3610
7cells per well) coated with type I rat tail
collagen (BD Biosciences, Bedford, MA), and incubated at 37uC
with 5% CO2 overnight. Nonadherent cells and debris were
discarded and adherent cells were washed once with EGM-2
medium, and grown in EGM-2 medium. Medium was changed
daily for 7 days and then every other day until first passage. After
7–10 days, monolayers of cobblestone-appearing cells appeared.
Immunoflurescence Microscopy
Cells were grown on 24 well tissue culture dishes to 80%
confluence, and fixed with 4% paraformaldehyde (Electron
Microscopy Services Inc.). Cells were blocked in 5% normal donkey
serum (Chemicon) for 1 hour. Primary antibody was added (16100
dilution) in PBS, and incubated with primary antibodies 3 hours to
overnight at room temperature. The following primary anti-
bodies were used: Mouse, goat, and rabbit IgG (R&D Systems),
CD31; mouse monoclonal, clone LCI-4, Santa Cruz Biotech-
nology Catalog #SC-80912), CD105; mouse monoclonal, clone
MEM-229, Santa Cruz Biotechnology Catalog #SC-51594),
CD117; rabbit polyclonal, Santa Cruz Biotechnology Catalog
#SC-168), CD144; goat polyclonal, Santa Cruz Biotechnology
Catalog # SC-6458),VEGFR2(Flk-1; mouse monoclonal, clone A-
3, Santa Cruz Biotechnology Catalog # SC-6251), eNOS (rabbit
polyclonal, Santa Cruz Biotechnology Catalog #SC-654), CD133
(goat polyclonal, Santa Cruz Biotechnology Catalog # SC-19365).
Alexa Fluor conjugated 488 or 555 donkey anti-mouse, goat or
rabbit secondary antibody (Molecular Probes) was added at a
dilution of 1:500 for 1 hour at room temperature. Nuclei were
stained with 49,6-diamidino-2-phenylindole (DAPI). Immunofluo-
rescent images were obtained using a Zeiss Axiovert 200 inverted
fluorescence microscope and Zeiss LD Achroplan 106 and 206
objectives using identical exposure times between antibodies.
Images were merged using Zeiss Axiovision software.
Immunophenotyping and Acetylated LDL Uptake by
Flow cytometry analysis
Cells were dissociated to a single cell suspension using 0.05%
Trypsin-EDTA, resuspended in DMEM/F12 with HEPES
supplemented with 10% FBS (Staining Medium), and pelleted
by centrifugation at 30 x g. Cells were incubated with primary
antibodies for 1 h at 4uC. Porcine specific antibodies used for flow
cytometry analysis included the following: CD31 (PECAM)
(mouse monoclonal, clone LCI-4, AbD Serotec. Oxford, UK),
CD45 (mouse monoclonal, clone K252.1E4, Santa Cruz Biotech-
nology Catalog # SC-59065), CD105 (Endoglin); mouse mono-
clonal, clone MEM-229, Santa Cruz Biotechnology Catalog
#SC-51594), CD133 (mouse monoclonal, clone AC133, Miltenyi
Biotec). Alexa Fluor conjugated 488 donkey anti-mouse antibody
(Molecular Probes) was used to detect primary antibodies. Primary
antibodies were incubated at 1:10 dilution, secondary antibodies
were incubated at 1:200 dilution. Uptake of acetylated LDL was
determined by incubation of LOEPCs with 10 mg/ml Alexa Fluor
conjugated 488 Dil-Ac-LDL (Molecular Probes) in EGM-2
medium 3 hours at 37uC.
Flow cytometry analysis was performed on a BD FACSCalibur.
100,000 events per condition were collected. Flow cytometry data was
gated in the FSC vs. SSC plots to exclude dead or clumped cells.
Cytometry data were analyzed using FCS Express (DeNovo Software).
Effects of Statins on In Vivo Mobilization and In Vitro
Derivation of LOEPCs from Porcine Peripheral Blood
Peripheral blood was obtained from eight healthy pigs (11–14
weeks old, 4069 kg, five males, three females) before and after
treatment with pravastatin for three days (4 mg/kg orally).
Mononuclear cells were isolated using the methods described
above. Mononuclear cells were plated at the density of 3610
7 cells
per well on six-well plates. After culture in EGM-2 medium for 14
days, cells were trypsinized and total cell number per well was
determined using a hemocytometer. The percentage of PE-
CAM(+) cells per well were determined by flow cytometry using
the protocol described above. The number of PECAM(+) cells per
1610
7 blood MNCs plated was determined as the product of total
cells per well6percentage of PECAM(+) cells per well. The effect
of statin treatment on the in vitro derivation of LOEPCs was
determined in MNCs obtained from normal pigs (not treated with
pravastatin), and treated with pravastatin or simvastatin (10 nM to
10 mM) added 24 hours after plating.
LOEPCs Colony-Forming Assays
Early passage LOEPCs (passages 3-5) were seeded onto six-well
plates precoated with type I rat tail collagen at clonal density, 500
Statins, EPCs, and Capillary Density
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either left untreated (control) or treated with pravastatin (100 nM
to 10 mM, Calbiochem, Catalog #524403), simvastatin (100 nM
to 10 mM, Calbiochem, Catalog #567021) or Akt inhibitor IV
(Calbiochem, Catalog #124015). Seven days after plating, cell
colonies were enumerated by phase contrast microscopy at 40x
magnification, followed by trypsinization and enumeration of total
cells per well.
Western Blot Analysis
Cells were harvested in homogenization buffer and total
protein content was quantified using Bio-Rad’s DC Protein
Assay. Samples were separated on 10% SDS-PAGE gels, and
transferred to PVDF membranes. Blots were probed with the
following primary antibodies: Akt (rabbit polyclonal antibody,
Cell Signaling Technology Catalog #9272; 1:1000 dilution,
overnight at 4uC), Phospho-Akt (Ser473,736E11, rabbit
monoclonal antibody, Cell Signaling Technology Catalog
#3787; 1:1000 dilution, overnight at 4uC), GAPDH (V-18,
goat polyclonal antibody, Santa Cruz Biotechnology Catalog
#sc-20357; 1:300 dilution overnight at 4uC). Protein bands
were detected by chemiluminescence using horseradish perox-
idase conjugated secondary antibodies (WestPico kit, Pierce
Biotechnology, 1:5000 dilution for 1 hour at room tempera-
ture), and quantiated by densitometry (Bio-Rad, Quantity One
software).
Matrigel Cord Formation Assay
LOEPCs were plated at a density of 5,000 cells per well in a 96
well tissue culture plates coated with 50 mL of Matrigel (BD
Biosciences) per well, and observed up to five days for capillary
tube formation. Wells were imaged 48 hours after cells were plated
to Matrigel using a Nikon phase contrast microscope and a 2x
objective. Images were captured using a Canon EOS digital
camera and associated software. Total vessel length and the
number of branch points were determined from the captured
images using ImageJ. Experiments were performed in triplicate.
Significant differences in vessel length and number of branch
points with each treatment was determined using an one-way
ANOVA with a Holm-Sidak post-hoc test, p,0.05.
Hibernating Myocardium Model
Hibernating myocardium was produced as previously described
[10]. Briefly, pigs were sedated (Telazol; tiletamine 50 mg/mL
and zolazepam 50 mg/mL)/xylazine (100 mg/mL, 0.022 mg/kg
i.m.), intubated and ventilated with 0.5–2% isoflurane-oxygen
mixture. Through a limited pericardiotomy, the proximal LAD
was instrumented with a Deltrin occluder (1.5 mm i.d.).
Antibiotics (cefazolin, 25 mg/kg and gentamicin, 3 mg/kg i.m.)
were given 1-hour before surgery and repeated after closing the
chest. Following surgery analgesia was perfomed by intercostal
nerve block (0.5% Marcaine), intramuscular doses of butorphanol
(2.2 mg/kg q6 h) and flenixin (1–2 mg/kg q.d.).
Quantitative Immunohistochemistry of Capillary Density
Samples adjacent to LAD (hibernating) and posterior descend-
ing arteries (normal) were obtained for immunohistochemical
studies. To identify effects on myocardial capillary density, frozen
tissue sections (5 mm) were incubated with anti-PECAM1 (clone
LCI-4, 1:100 dilution, AbD Serotec). Images were acquired with a
confocal microscope (Bio-Rad MRC 1024). The number of




Data are expressed as means 6 SEM unless otherwise specified.
Statistical comparison between PECAM (+) cell growth from
porcine peripheral blood before and after treatment with
pravastatin in vivo was performed using paired t-test. All other
comparisons were performed using one-way ANOVA; p,0.05 is
considered as statistically significant.
Results
Derivation and Characterization of Late Outgrowth
Endothelial Progenitor Cells from Pigs
We derived LOEPCs from porcine blood mononuclear cells.
LOEPC grew as colonies or clones upon initial outgrowth from
blood mononuclear cells (Figure 1A), and were passaged serially.
Porcine LOEPCs expressed antigens found in endothelial cells,
and described in LOEPCs from human blood [7] including
PECAM (CD31), VE-Cadherin (CD144), VEGFR2, c-kit
(CD117), endothelial specific nitric oxide synthase (eNOS), and
Tie 2 (Figure 1B). Additionally, live porcine LOEPCs retained cell
surface expression of the endothelial markers CD31, CD105, and
absorbed acetylated LDL, but were negative for the early
outgrowth EPC marker CD133, and hematopoietic cell marker
CD45 (Figure 2). Collectively, porcine LOEPCs have an antigen
profile and activities consistent with features found in human
LOEPCs.
Pravastatin Mobilizes LOEPCs into the Blood Stream
Given the positive effects of statins on the quantity and activity
of early outgrowth EPCs shown previously, we hypothesized that
statin therapy similarly mobilizes LOEPCs into the bloodstream
when given to animals in vivo [12]. To test this hypothesis, we
collected blood samples from pigs at baseline, and after treatment
with pravastatin 160 mg daily for three days in vivo. Blood
mononuclear cells were obtained and cultured under conditions
that support growth of LOEPCs for 14 days in the absence of
further statin treatment. We then determined the quantity of
CD31+ LOEPCs per 1610
7 MNCs plated. We found that short-
term therapy with pravastatin efficiently mobilizes LOEPCs,
increasing the number of LOEPCs greater than two-fold
(37,78865,738 pravastatin vs. 17,05062,517 untreated, p#0.05-
Figure 3).
Statins Enhance Derivation of LOEPCs from Mononuclear
Cells In Vitro
We hypothesized that statin treatment may augment the growth
or survival of LOEPCs in culture. To determine the effect of statin
therapy on the derivation of LOEPCs, both pravastatin and
simvastatin were added to MNCs from normal pigs in vitro, and
the quantity of CD31+ cells per 1610
7 cells plated was determined
by flow cytometry after 14 days of growth. Both pravastatin and
simvastatin treatment of normal porcine MNCs in vitro increased
the number of LOEPCs obtained greater than three-fold
(62,24769,684 CD31+ cells/1610
7 MNCs for pravastatin-
100 nM, 59,83366,999 CD31+ cells/1610
7 MNCs for simvasta-
tin-100 nM, 17,05062,518 CD31+ cells/1610
7 MNCs untreat-
ed). While higher doses of pravastatin (1 mMt o1 0mM) did not
have a statistically significant effect on the quantity of LOEPCs
obtained, simvastatin at high doses (10 mM) resulted in cytotoxicity
(Figure 4). The concentration range of statins added to LOEPCs in
our study is also clinically relevant. In normal human subjects,
40 mg of pravastatin taken daily provides a steady state level of
pravastatin ,100 nanomolar in the bloodstream [11].
Statins, EPCs, and Capillary Density
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derivation of LOEPCs from MNCs, facilitating their isolation
and expansion in culture.
Statins Augment Clonal Growth of LOEPCs
Predominantly by AKT Independent Effects
A key difference between LOEPCs and EOEPCs is their ability
to grow under limiting dilution or clonal conditions [5,6].
Hematopoietic cell progenitors are defined by their ability to
form colonies based on differences in proliferative or differentia-
tion potential, and the same principal of clonal growth was used to
define LOEPCs from humans [7]. Clonogenic growth is a defining
assay to distinguish EOEPCs from LOEPCs. The capacity for
replating and growth under clonal conditions is a feature specific
for the LOEPC and provides additional evidence to support our
characterization data [12]. We hypothesized that one effect of
pravastatin on LOEPCs was to promote their growth and survival
in culture. Additionally, some reports suggested that different
statins may have stimulatory vs. inhibitory effects on angiogenesis,
but it remains unclear if this effect is true of all statins, or if more
subtle chemical differences between compounds may underlie
potential differential effects [13,14]. We compared the effects of
the hydrophilic statin pravastatin vs. the hydrophobic statin
simvastatin on LOEPC colony growth (see Figure 5). Both
pravastatin and simvastatin augmented the growth of LOEPCs
with the greatest effect noted at 100 nM. Pravastatin (100 nM)
increased the number of LOEPC colonies 60% (95.8614 colonies
formed/500 cells plated vs. 59.764.5 for untreated cells, p#0.05),
while simvastatin (100 nM) increased the number of LOEPCs
colonies obtained by 38% (82.167.3 colonies/500 cells plated).
Interestingly, high concentrations of simvastatin ($10 mM) but not
pravastatin resulted in cytotoxicity indicating a differential effect of
statin drugs on LOEPCs colony growth.
As statins have been shown to mediate their effects on early
outgrowth EPCs via the PI-3 kinase/AKT pathway, we asked
whether statin treatment of porcine LOEPCs induces AKT
phosphorylation [12]. We found that statin treatment in vitro
(100 nM) increased AKT phosphorylation 20% when compared
with untreated cells (0.82360.04 densitometric units vs. 1.0560.08
for pravastatin treated cells, vs. 1.0260.1 for simvastatin treated
cells). We verified the specificity of our western blot detection
method using an inhibitor of AKT activity (Figure 6A).
To determine the functional significance of AKT activity on
clonal growth of LOEPCs, we treated control and statin exposed
cells with an AKT-specific antagonist (AKT inhibitor IV). We
used 100 nM AKT inhibitor IV for these experiments because we
found higher concentrations resulted in cell death in the majority
of the cell cultures. We found that inhibition of AKT activity in
LOEPCs reduced the number of colonies formed by 70% (596
3.9 vs. 17.563.5 colonies/500 cells plated with AKT inhibitor
(100 nM), p#0.05) in non-statin treated cells, 65% in simvastatin
treated cells (8260.7 vs. 29.263.4, p#0.05), and 63% in
pravastatin treated cells (95.860.5 vs. 37.363.7, p#0.05, Figure
6B). These findings indicate the majority of the growth and
survival properties of LOEPCs are sensitive to AKT inhibition. In
contrast to early outgrowth EPCs, statin treatment of LOEPCs in
Figure 1. Characterization of porcine late outgrowth endothelial progenitor cells (LOEPCs). Panel A: Phase contrast image of porcine
LOEPC colony (upper image 2X magnification, lower image 10 x magnification, scale bar 500 microns). Panel B: Representative microscopic fields of
LOEPCs are shown illustrating antigens characteristic of LOEPCs and endothelial cells; PECAM (CD31), VE-Cadherin (CD144), VEGFR2 (FLK1/KDR), c-Kit
(CD117), endothelial specific nitric oxide synthase (eNOS), and Tie 2. Scale bars=500 um. Results shown are representative of at least three
independent experiments from separate animals.
doi:10.1371/journal.pone.0024868.g001
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relative to untreated controls. These results suggest that statins
may act via an AKT independent pathway to promote clonal
growth of LOEPCs. The findings support a differential, pleiotropic
effect of statins to support the growth and survival of LOEPCs,
which may be reflective of statin effects in vivo.
Effects of HMG-CoA Reductase Inhibitors on Matrigel
Tube Formation in Porcine LOEPCs
The preceding experiments show that both the HMG-CoA
reductase inhibitors Pravastatin and Simvastatin increase the
clonal growth of LOEPCs in culture. We next determined the
effects of HMG-CoA reductase inhibitors on a different function of
endothelial cell biology, formation of tubules in Matrigel. Prior
studies have shown that little or no cell proliferation occurs in the
Matrigel tube formation assay, but reliably models the process of
angiogenic tube formation of endothelial cells in vitro [15].
Therefore the goal of these experiments was to determine if statins
differentially affected endothelial cell differentiation and angio-
genesis independent of the growth promoting effects of statins
[16]. LOEPCs were plated to solidified Matrigel in the absence or
presence of Pravastatin, Simvastatin or Atorvastatin (100 nM
each). Cells were imaged with phase contrast microscopy 24 hours
after plating to Matrigel. Vessel segment length and the number of
Figure 2. Flow cytometry analysis of porcine late outgrowth endothelial progenitor cells (LOEPCs). Representative flow cytometry plots
of cultured late outgrowth endothelial progenitor cells expanded from initial clonal outgrowths from blood mononuclear cells. LOEPCs were
analyzed with mouse monoclonal antibodies to the following antigens: Mouse IgG1, Mouse anti-pig CD31, CD105, CD133, and CD45. Primary
antibodies were detected with Alexa Fluor 488 conjugated donkey anti-mouse antibodies. Results are representative of at least three independent
experiments from separate animals.
doi:10.1371/journal.pone.0024868.g002
Figure 3. Oral Pravastatin Promotes the Outgrowth of LOEPCs
from Blood Mononuclear Cells. Pigs were treated with a placebo or
pravastatin (4 mg/kg orally) daily for three consecutive days. Blood
mononuclear cells were obtained on day three, and cultured on type I
collagen coated dishes to derive LOEPCs. The quantity of LOEPCs per
3610
7MNCs plated was determined using flow cytometry to determine
the number of PECAM positive cells after 14 days in culture. The data
are presented as the means 6 SEM from eight different animals.
*p ,0.01 vs. control using a paired t-test.
doi:10.1371/journal.pone.0024868.g003
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We found that the total segment length of vessels formed in
Matrigel was significantly reduced upon incubation with Pravastatin,
Simvastatin and Atorvastatin (Figure 7A and B, p,0.05), while
Simvastatin and Atorvastatin significantly increased the number of
vessel branch points (Figure 7A and C, p,0.05) in comparison with
Figure 4. In Vitro Pravastatin and Simvastatin Promotes Outgrowth of LOEPCs from Blood Mononuclear Cells. Mononuclear cells were
obtained from normal young pigs and cultured on type I collagen to derived LOEPCs. The quantity of LOEPCs per 3610
7MNCs plated was determined
using flow cytometry for PECAM positive cells after 14 days in culture. The data are presented as the means 6 SEM from eight different animals.
*p ,0.05, ** p,0.01 vs. control using a paired t-test.
doi:10.1371/journal.pone.0024868.g004
Figure 5. In Vitro Pravastatin and Simvastatin Promotes Growth of LOEPCs under Clonogenic Conditions. LOEPC cell lines from pigs
were plated under limiting dilution conditions in the absence or presence of pravastatin or simvastatin. The number of LOEPCs was determined after
seven days of growth with or without statin. The data are presented as the means 6 SEM from eight independent experiments.
doi:10.1371/journal.pone.0024868.g005
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24868untreated cells. The sum of vessel segments in untreated cells, or after
treatment with Pravastatin, Simvastatin, and Atorvastatin was the
same in all conditions, consistent with a lack of proliferation of
endothelial cells when plated onto Matrigel as previously shown [16].
The findings are consistent with higher potency statins being more
effective than Pravastatin in promotion of in vitro angiogenic branch
formation in LOEPCs. Moreover, our findings indicate divergent
effects of statins on LOEPC clonal growth versus in vitro
angiogenesis.
Pravastatin Therapy Increases Myocardial Capillary
Density in Hibernating Myocardium
To assess the in vivo significance of statin effects on porcine
LOEPCs and cardiac angiogenesis, we examined the effect of
statin treatment on porcine myocardium. Conflicting studies have
suggested that statin therapy may augment or impair angiogenesis
in chronically ischemic myocardium [3,17]. To determine the
effect of pravastatin on angiogenesis in the chronically ischemic
heart, we measured the capillary density in myocardial tissue
obtained from the chronically ischemic anterior wall and non-
ischemic posterolateral wall segments from both untreated animals
and those treated with pravastatin for 30 days. We found that
pravastatin treatment increased the number of CD31+ capillaries
per square mm of myocardial tissue by 46% (1769.16116.7 vs.
1210.66151.6 capillaries/mm
2,p #0.05) in the hibernating LAD
territory, and 37% in the remote, non-ischemic territory
(1495.2693.4 vs. 1095.16123.0, p#0.05, Figures 8A and B).
We have performed similar analysis of CD31+ vessels in the heart
using immunoperoxidase labeled secondary antibodies. We found
that immunoperoxidase staining did not enhance the visualization
of CD31+ cells in the heart. The CD31+ vessels appear small
because they are cut in 90u cross section (transversely). The images
shown are truly representative of the effect of pravastatin versus no
treatment on capillary density in the chronically ischemic heart.
The image shown in Figure 8A is representative of one of .400
microscopic fields that were quantified per animal to determine
the capillary density. The quantification of the images in panel B
reflects the statistically significant difference noted between
untreated and pravastatin treated animals.
In previously published work, we found that therapy with
pravastatin increased myocyte nuclear density in the chronically
ischemic heart with proliferation of small cardiac myocytes [2].
These findings are consistent with an effect of pravastatin that
increases the myocardial capillary density to match the microcir-
culation with formation of new and smaller cardiac myocytes.
Discussion
From these studies we identified the following novel conclusions:
1) LOEPCs are effectively mobilized into the blood after short-term
therapy with pravastatin, 2) both pravastatin and simvastatin
facilitate the derivation of LOEPCs from peripheral blood
mononuclear cells, 3) low concentrations of both pravastatin and
simvastatin enhance clonogenic growth of LOEPCs in vitro, while
higher concentrations of simvastatin have toxic effects, 4) antago-
nism of AKT signaling impairs clonogenic growth of LOEPCs, but
does notimpairthepositiveeffectofstatinsonLOEPC growth, 5)in
vivo pravastatin increases capillary density in chronically ischemic
myocardium in parallel with increased myocyte nuclear density.
Figure 6. Clonogenic Growth of LOEPCs is Sensitive to AKT inhibition, while the Effect of Pravastatin and Simvastatin on LOEPC
Clonogenic Growth is Not. Panel A-Western blot analysis showing both pravastatin and simvastatin activate AKT phosphorylation, and AKT
inhibitor IV blocks the phosphorylation of AKT in LOEPCs. Panel B-LOEPCs were grown under clonogenic conditions with or without an AKT inhibitor
(100 nM), in the presence or absence of pravastatin or simvastatin (100 nM each) to determine if the effect of statins on LOEPC clonogenic growth as
sensitive to AKT inhibition. n=6 independent experiments. * p,0.05 vs. No Akt inhibitor IV.
doi:10.1371/journal.pone.0024868.g006
Statins, EPCs, and Capillary Density
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EPCs
The identification and measurement of EPCs has evolved
considerably since their original description by Ashahara et al.
[18]. However, LOEPCs lack specific markers to identify the cells
de novo and quantification of EPCs relies on culture-based
assays. Differences in adherence to either fibronectin or type I
collagen coated dishes distinguish early and late outgrowth EPCs
growth, respectively. Early outgrowth EPCs are functionally
distinct from LOEPCs in that they are unable to proliferate under
clonogenic conditions, express cell surface markers consistent
with monocytes, and fail to form functional vessels when
transplanted in vivo [5,6]. While the relationship between early
outgrowth EPCs and cardiovascular disease risk factors has been
Figure 7. Statins Differentially Affect Angiogenesis of LOEPCs in Vitro. Panel A: Representative photomicrographs of porcine LOEPCs
plated on polymerized Matrigel for 24 hours with no drug treatment (Control), or Pravastatin, Simvastatin or Atorvastatin (100 nM each). Images are
representative of three independent experiments. Scale bar=500 microns. Panel B: Mean vessel length was measured from photomicrographs.
Means +/2 SEM are shown for three independent experiments. Significant differences from untreated cells (Control) are indicated by * (p,0.05).
Panel C: Branch Point Determination-the number of branch points within LOEPCs plated on Matrigel was determined from each photomicrograph.
The means +/2 SEM are shown for three experiments. Significant differences from untreated cells (Control) are indicated by * (p,0.05).
doi:10.1371/journal.pone.0024868.g007
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risk and LOEPC growth remain to be defined. Given the fact that
LOEPCs proliferate in culture, this trait facilitates studies of the
effects of aging of LOEPC growth and activity while EOEPCs
cannot be studied in this manner. Furthermore, the clonogenic
growth assay for LOEPCs may be applied as we have used it to
study effects of statins to identify novel agents that promote their
growth and survival in vitro, that may then be translated
angiogenesis in vivo.
The Origins of Late Outgrowth EPCs
Early outgrowth EPCs are identified by expression of CD34,
VEGFR2 and CD133. Recent evidence indicates that these cells
also express CD45 (indicating a leukocyte cell type) and cell sorting
experiments have illustrated that these cells are a hematopoietic
progenitor and form monocytes in vitro [20]. Additionally, cell
sorting experiments of mononuclear cells from umbilical cord and
adult blood has shown that LOEPCs can be obtained from
CD34+ VEGFR2+ CD45- and CD133- cell populations, while
CD34+ CD45+ cells also express CD133, and generate monocytic
cells that have properties consistent with early outgrowth EPCs
[20].
S i n c el a t eo u t g r o w t hE P C sl a c kspecific identifying cell
surface markers, genetic marking to facilitate fate mapping
studies in vivo are currently not feasible. It is plausible that
L O E P C sa r ed e r i v e df r o mt h eb o n em a r r o w ,o rt h e ya r i s e
directly from the vessel wall [21]. Endothelial cells with
hemogenic potential have been described in the embryonic
yolk sac, dorsal aorta, and fetal liver that originate from the
vessel walls [22]. Yolk sac derived hemangioblasts, bi-potential
cells producing both hematopoietic and endothelial cells have
been described in vitro from embryonic stem cells [23]. In vivo
fate mapping experiments indicate that multiple cellular sources
contribute to yolk sac blood islands in development [24].
LOEPCs in adults may similarly be derived from a poly-
clonal origin. Specific identifying features to track the fate of
LOEPCs in vivo are required to determine their contribution to
vessel homeostasis under both normal conditions and in
atherosclerotic vascular disease, as well as neoplastic and
ischemic angiogenesis.
Figure 8. Pravastatin Increases Myocardial Capillary Density in Animals with Chronic Myocardial Ischemia In Both Hibernating
Myocardium and the Non-ischemic Remote Myocardium. Panel A-Representative immunofluorescence images of myocardial tissue from
untreated or Pravastatin treated pigs with hibernating myocardium. Scale bar=500 microns. Panel B-Quantitative assessment of CD31+ cells per
square millimeter in chronically ischemic hibernating myocardium in the territory of the left anterior descending artery, and the opposite non-
ischemic posterolateral wall, n=6 animals in pravastatin treated group, n=5 non-statin treated animals, p,0.05.
doi:10.1371/journal.pone.0024868.g008
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Outgrowth EPC Growth, Relevance to Angiogenesis In
Vivo
Statins are recommended therapy for the primary and
secondary prevention of coronary artery disease [25,26,27]. Most
recent guidelines advocate treating to a target LDL cholesterol
,70 mg/dL, because of the effect on cardiovascular disease
outcomes in large clinical trials [27,28]. However, several groups
have reported an apparent biphasic or differential effect of statins,
in that low concentrations of statins appear to promote endothelial
cell proliferation, migration and differentiation, while higher doses
impair these effects [3,17,29]. One mechanism may be that lower
dose statin therapy may activate AKT signaling, but impair the
function of isoprenylated proteins of the Ras family or lamins,
which have essential functions in cell proliferation and division
[30]. An alternative hypothesis would be that the effect of statins
on angiogenesis is not tied to statin dose necessarily, but to
differences in lipophillicity [31] and the intracellular concentration
of statins. In our study, we found effects of pravastatin that
promoted clonogenic growth of LOEPCs (10 mM), while the same
dose of simvastatin had toxic effects on the cells. The effects of
statins in this cell based assay cannot alter lipoprotein levels (i.e.
low density lipoprotein), but may function through direct effects on
cholesterol biosynthesis affecting lipid modifications of prenylated
proteins. This suggests the difference in chemical properties of
these two statins may underlie the differences in LOEPC growth
and survival.
Our findings show that statins increase both the derivation of
LOEPCs from blood and growth under clonogenic conditions.
While AKT activity plays a role in their clonogenic growth,
antagonism of AKT does not completely inhibit the effect of statins
to promote LOEPC growth. Additionally, in the chronically
ischemic heart, we find that pravastatin therapy increases the
myocardial capillary density in both chronically ischemic myocar-
dium, and the less affected remote myocardial territory. These
findings indicate that both in vitro and in vivo statins promote the
growth of nascent endothelial cells. Additionally, recent evidence
suggests that intracoronary injection of LOEPCs in pigs that have
sustained a myocardial infarction may have a beneficial effect on
heart remodeling as compared with similar therapy with
mesenchymal stem cells [32], suggesting a potential role for
LOEPC therapy in animal models and patients with acute
myocardial infarcts. LOEPCs may have an advantage over other
adult stem cell therapies for acute heart disease including
mesenchymal stem cells or cardiosphere derived cells in that they
can readily obtained from venous blood. This application of
LOEPCs adds significance to our findings that LOEPCs can be
expanded in vitro by the addition of pravastatin.
Study Limitations
Our study shows that LOEPCs can be derived from young pigs
and have markers, activity and growth properties that match
LOEPCs derived from humans. The success of these studies may
be due to the age of the animals used in this study. Remarkably,
LOEPCs in humans have both low and high proliferative
potential, and cells derived from adults predominantly have low
proliferative potential. Though not addressed directly in the
current manuscript, we found no difficulties in repeated passaging
of LOEPCs to suggest they developed senescence. Similar studies
of the effects of statins in LOEPCs from humans would be
informative to determine if the findings hold true across species.
Furthermore, it is currently difficult to know the precise role of the
LOEPC in formation of new vessels in the ischemic heart or other
organs, as a lack of cell specific markers for LOEPCs exist to
perform in vivo cell fate tracking.
Acknowledgments
We acknowledge the assistance of the Confocal Microscope and Flow
Cytometry Facility in the School of Medicine and Biomedical Sciences,
University at Buffalo. We also thank Anne Coe, Deanna Gretka, and
Elaine Granica for technical support.
Author Contributions
Conceived and designed the experiments: WW TC GS JMC. Performed
the experiments: WW TC GS. Analyzed the data: WW JKL GS JMC TC.
Contributed reagents/materials/analysis tools: WW TC GS. Wrote the
paper: JKL TC.
References
1. Gheorghiade M, Bonow RO (1998) Chronic heart failure in the United States.
Circulation 97: 282–289.
2. Suzuki G, Iyer V, Cimato T, Canty JM Jr. (2009) Pravastatin improves function
in hibernating myocardium by mobilizing CD133+ and c-kit+ bone marrow
progenitor cells and promoting myocytes to reenter the growth phase of the
cardiac cell cycle. Circulation Research 104: 255–64.
3. Boodhwani M, Mieno S, Voisine P, Feng J, Sodha N, et al. (2006) High-dose
atorvastatin is associated with impaired myocardial angiogenesis in response to
vascular endothelial growth factor in hypercholesterolemic swine. J Thorac
Cardiovasc Surg 132: 1299–1306.
4. Bearzi C, Leri A, LoMonaco F, Rota M, Gonzalez A, et al. (2009) Identification
of a coronary vascular progenitor cell in the human heart. Proc Natl Acad Sci
106: 15885–90.
5. Hirschi KK, Ingram DA, Yoder MC (2008) Assessing identity, phenotype and
fate of endothelial progenitor cells. Arteriosclerosis Thrombosis and Vascular
Biology 28: 1584–95.
6. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, et al. (2007)
Redefining endothelial progenitor cells via clonal analysis and hematopoietic
stem/progenitor cell principals. Blood 109: 1801–9.
7. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004)
Identification of a novel hierarchy of endothelial progenitor cells using human
peripheral and umbilical cord blood. Blood 104: 2752–60.
8. Broxmeyer HE, Srour E, Orschell C, Ingram DA, Cooper S, et al. (2006) Cord
blood stem and progenitor cells. Methods in Enzymology 419: 439–73.
9. Ingram DA, Krier TR, Mead LE, McGuire C, Prater DN, et al. (2007) Clonogenic
endothelial progenitor cells are sensitive to oxidative stress. Stem Cells 25: 297–304.
10. Fallavollita JA, Perry BJ, Canty JM Jr. (1997) 18F-2-deoxyglucose deposition and
regional flow in pigs with chronically dysfunctional myocardium. Evidence for
transmural variations in chronic hibernating myocardium. Circulation 95: 1900–9.
11. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of
pharmacokinetic events. Clin Pharmacokinet 39: 397–412.
12. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, et al. (2001) HMG-
CoA reductase inhibitors (statins) increase endothelial progenitor cells via the
PI3-kinase/AKT pathway. J Clin Invest 108: 391–7.
13. Skaletz-Rorowski A, Kureishi Y, Shiojima I, Walsh K (2004) The pro- and
antiangiogenic effects of statins. Semin Vasc Med 4(4): 395–400.
14. Skaletz-Rorowski A, Walsh K (2003) Statin therapy and angiogenesis. Curr
Opin Lipidol 14(6): 559–603.
15. Arnaoutova I, Kleinman HK (2010) In vitro angiogenesis: endothelial cell tube
formation on gelled basement membrane extract. Nature Protocols 5: 628–635.
16. Kubota Y, Kleinman HK, Martin GR, Lawley TJ (1988) Role of laminin and
basement membrane in the morphologic differentiation of human endothelial
structures into capillary-like structures. J Cell Biol 107: 1599–1610.
17. Urbich C, Dernbach E, Zeiher AM, Dimmeler S (2002) Double-edged role of
statins in angiogenesis signaling. Circ Res 90: 737–744.
18. Ashahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation
of putative progenitor endothelial cells for angiogenesis. Science 275: 964–7.
19. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003)
Circulating endothelial progenitor cells, vascular function, and cardiovascular
risk. New England Journal of Medicine 348: 593–600.
20. Case J, Mead LE, Bessler WK, Prater D, White HA, et al. (2007) Human
CD34+AC133+VEGFR2+ cells are not endothelial progenitor cells but distinct,
primitive hematopoietic progenitors. Exp Hematol 35: 1109–18.
21. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F,
et al. (2007) Endothelial outgrowth cells are not derived from CD133+ cells or
CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 27: 1572–9.
22. Yoder MC (2010) Is endothelium the origin of endothelial progenitor cells?
Arterioscler Thromb Vasc Biol 30: 1094–1103.
Statins, EPCs, and Capillary Density
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e2486823. Oberlin E, Tavian M, Blazsek I, Peault B (2002) Blood-forming potential of
vascular endothelium in the human embryo. Development 129: 4147–4157.
24. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G (1998) A common
precursor for hematopoietic and endothelial cells. Development 125: 725–732.
25. Ueno H, Weissman IL (2006) Clonal analysis of mouse development reveals a
polyclonal origin for yolk sac blood islands. Developmental Cell 11: 519–533.
26. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary
prevention of cardiovascular diseases with statin therapy: A meta-analysis of
randomized controlled trials. Arch Intern Med 166: 2307–2313.
27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004)
Intensive versus moderate lipid lowereing with statins after acute coronary
syndromes. N Engl J Med 350: 1495–1504.
28. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive
lipid lowering with Atorvastatin in patients with stable coronary disease. N Engl
J Med 352: 1425–35.
29. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic
effects on angiogenesis. Circulation 105: 739–745.
30. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2009)
Molecular basis of statin-associated myopathy. Atherosclerosis 202: 18–28.
31. Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to
distinct pharmacologic and pleiotrophic actions. Am J Cardiol 96: 11F–23F.
32. Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, et al. (2010) Differential
effects of progenitor cell populations on left ventricular remodeling and
myocardial neovascularization after myocardial infarction. J Am Coll Cardiol-
ogy 55: 2232–43.
Statins, EPCs, and Capillary Density
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24868